Article
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.
ESMO open - 1 Mar 2026
Hadoux J, Hernando J, Wong K H, Do Cao C, Lasolle H, Buffet C, Benisvy D, Illouz F, Schneegans O, Varnier R, Drui D, Zanetta S, Hescot S, Muller M, Nascimento C, Roudaut N, Khanal M, Zheng S, Li X, Singh R, Tian W, Afonso A S, Houot B, Borget I, Segall G
Abstract excerpt
BACKGROUND: The single-arm phase I/II LIBRETTO-001 trial demonstrated durable efficacy with selpercatinib in patients with rearranged during transfection (RET)-mutation-positive medullary thyroid cancer (MTC). RECALIB-RET compared effectiveness outcomes using a real-world external control (EC) arm of patients with RET-mutation-positive MTC treated with standard of care (SoC) versus selpercatinib (LIBRETTO-001)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.